Do small lapses predict relapse to smoking behavior under bupropion treatment?

E. Paul Wileyto, Freda Patterson, Raymond Niaura, Leonard H. Epstein, Richard A. Brown, Janet Audrain-McGovern, Larry W. Hawk, Caryn Lerman

Research output: Contribution to journalArticle

Abstract

Although bupropion is known to be an effective aid to smoking cessation, little is known about its mode of action. In the present study we tested the hypothesis that bupropion reduces the likelihood that a smoking lapse, or slip, leads to a subsequent relapse. This hypothesis was tested in the context of a clinical trial of bupropion as a smoking cessation aid, using Cox regression and representing lapse history as a discrete time-varying covariate. Bupropion treatment reduced the probability of relapse during the treatment phase (hazard ratio, or HR =.421, p≤.000) but not during the follow-up phase (end of treatment to 6 months, HR =.896, p≤.67). As anticipated, having small lapses during treatment contributed to or predicted subsequent relapse, both during treatment (HR = 2.897, p≤.000) and during follow-up (HR = 2.320, p≤.008). Although an interaction was found between drug treatment and lapse history in predicting subsequent failure during the treatment phase, the finding suggested that drug slightly increased the effect of lapse on eventual failure during treatment (HR = 1.706, p≤ .012). No evidence was found that the effect of this interaction carried forward into follow-up (HR = 1.500, p≤.30). Although the mechanisms of action of bupropion may best be addressed in a human laboratory study, results from this clinical trial suggest that the effectiveness of bupropion treatment is not attributable to reducing the effect of a lapse in predicting relapse.

Original languageEnglish (US)
Pages (from-to)357-367
Number of pages11
JournalNicotine and Tobacco Research
Volume6
Issue number2
DOIs
StatePublished - Apr 2004

Fingerprint

Bupropion
Smoking
Recurrence
Smoking Cessation
Treatment Failure
History
Clinical Trials
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Wileyto, E. P., Patterson, F., Niaura, R., Epstein, L. H., Brown, R. A., Audrain-McGovern, J., ... Lerman, C. (2004). Do small lapses predict relapse to smoking behavior under bupropion treatment? Nicotine and Tobacco Research, 6(2), 357-367. https://doi.org/10.1080/1462220042000202463

Do small lapses predict relapse to smoking behavior under bupropion treatment? / Wileyto, E. Paul; Patterson, Freda; Niaura, Raymond; Epstein, Leonard H.; Brown, Richard A.; Audrain-McGovern, Janet; Hawk, Larry W.; Lerman, Caryn.

In: Nicotine and Tobacco Research, Vol. 6, No. 2, 04.2004, p. 357-367.

Research output: Contribution to journalArticle

Wileyto, EP, Patterson, F, Niaura, R, Epstein, LH, Brown, RA, Audrain-McGovern, J, Hawk, LW & Lerman, C 2004, 'Do small lapses predict relapse to smoking behavior under bupropion treatment?', Nicotine and Tobacco Research, vol. 6, no. 2, pp. 357-367. https://doi.org/10.1080/1462220042000202463
Wileyto, E. Paul ; Patterson, Freda ; Niaura, Raymond ; Epstein, Leonard H. ; Brown, Richard A. ; Audrain-McGovern, Janet ; Hawk, Larry W. ; Lerman, Caryn. / Do small lapses predict relapse to smoking behavior under bupropion treatment?. In: Nicotine and Tobacco Research. 2004 ; Vol. 6, No. 2. pp. 357-367.
@article{fe6fdc3eee8a45f39f90baa3c3c99a7e,
title = "Do small lapses predict relapse to smoking behavior under bupropion treatment?",
abstract = "Although bupropion is known to be an effective aid to smoking cessation, little is known about its mode of action. In the present study we tested the hypothesis that bupropion reduces the likelihood that a smoking lapse, or slip, leads to a subsequent relapse. This hypothesis was tested in the context of a clinical trial of bupropion as a smoking cessation aid, using Cox regression and representing lapse history as a discrete time-varying covariate. Bupropion treatment reduced the probability of relapse during the treatment phase (hazard ratio, or HR =.421, p≤.000) but not during the follow-up phase (end of treatment to 6 months, HR =.896, p≤.67). As anticipated, having small lapses during treatment contributed to or predicted subsequent relapse, both during treatment (HR = 2.897, p≤.000) and during follow-up (HR = 2.320, p≤.008). Although an interaction was found between drug treatment and lapse history in predicting subsequent failure during the treatment phase, the finding suggested that drug slightly increased the effect of lapse on eventual failure during treatment (HR = 1.706, p≤ .012). No evidence was found that the effect of this interaction carried forward into follow-up (HR = 1.500, p≤.30). Although the mechanisms of action of bupropion may best be addressed in a human laboratory study, results from this clinical trial suggest that the effectiveness of bupropion treatment is not attributable to reducing the effect of a lapse in predicting relapse.",
author = "Wileyto, {E. Paul} and Freda Patterson and Raymond Niaura and Epstein, {Leonard H.} and Brown, {Richard A.} and Janet Audrain-McGovern and Hawk, {Larry W.} and Caryn Lerman",
year = "2004",
month = "4",
doi = "10.1080/1462220042000202463",
language = "English (US)",
volume = "6",
pages = "357--367",
journal = "Nicotine and Tobacco Research",
issn = "1462-2203",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Do small lapses predict relapse to smoking behavior under bupropion treatment?

AU - Wileyto, E. Paul

AU - Patterson, Freda

AU - Niaura, Raymond

AU - Epstein, Leonard H.

AU - Brown, Richard A.

AU - Audrain-McGovern, Janet

AU - Hawk, Larry W.

AU - Lerman, Caryn

PY - 2004/4

Y1 - 2004/4

N2 - Although bupropion is known to be an effective aid to smoking cessation, little is known about its mode of action. In the present study we tested the hypothesis that bupropion reduces the likelihood that a smoking lapse, or slip, leads to a subsequent relapse. This hypothesis was tested in the context of a clinical trial of bupropion as a smoking cessation aid, using Cox regression and representing lapse history as a discrete time-varying covariate. Bupropion treatment reduced the probability of relapse during the treatment phase (hazard ratio, or HR =.421, p≤.000) but not during the follow-up phase (end of treatment to 6 months, HR =.896, p≤.67). As anticipated, having small lapses during treatment contributed to or predicted subsequent relapse, both during treatment (HR = 2.897, p≤.000) and during follow-up (HR = 2.320, p≤.008). Although an interaction was found between drug treatment and lapse history in predicting subsequent failure during the treatment phase, the finding suggested that drug slightly increased the effect of lapse on eventual failure during treatment (HR = 1.706, p≤ .012). No evidence was found that the effect of this interaction carried forward into follow-up (HR = 1.500, p≤.30). Although the mechanisms of action of bupropion may best be addressed in a human laboratory study, results from this clinical trial suggest that the effectiveness of bupropion treatment is not attributable to reducing the effect of a lapse in predicting relapse.

AB - Although bupropion is known to be an effective aid to smoking cessation, little is known about its mode of action. In the present study we tested the hypothesis that bupropion reduces the likelihood that a smoking lapse, or slip, leads to a subsequent relapse. This hypothesis was tested in the context of a clinical trial of bupropion as a smoking cessation aid, using Cox regression and representing lapse history as a discrete time-varying covariate. Bupropion treatment reduced the probability of relapse during the treatment phase (hazard ratio, or HR =.421, p≤.000) but not during the follow-up phase (end of treatment to 6 months, HR =.896, p≤.67). As anticipated, having small lapses during treatment contributed to or predicted subsequent relapse, both during treatment (HR = 2.897, p≤.000) and during follow-up (HR = 2.320, p≤.008). Although an interaction was found between drug treatment and lapse history in predicting subsequent failure during the treatment phase, the finding suggested that drug slightly increased the effect of lapse on eventual failure during treatment (HR = 1.706, p≤ .012). No evidence was found that the effect of this interaction carried forward into follow-up (HR = 1.500, p≤.30). Although the mechanisms of action of bupropion may best be addressed in a human laboratory study, results from this clinical trial suggest that the effectiveness of bupropion treatment is not attributable to reducing the effect of a lapse in predicting relapse.

UR - http://www.scopus.com/inward/record.url?scp=2542498831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542498831&partnerID=8YFLogxK

U2 - 10.1080/1462220042000202463

DO - 10.1080/1462220042000202463

M3 - Article

VL - 6

SP - 357

EP - 367

JO - Nicotine and Tobacco Research

JF - Nicotine and Tobacco Research

SN - 1462-2203

IS - 2

ER -